Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 16:17:1-7.
doi: 10.2174/1745017902117010001. eCollection 2021.

Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors

Dania Abu-Naser  1 , Sara Gharaibeh  2 , Ahmad Z Al Meslamani  3 , Qais Alefan  2 , Renad Abunaser  2
Affiliations

Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors

Dania Abu-Naser et al. Clin Pract Epidemiol Ment Health. .

Abstract

Background: Extrapyramidal Symptoms (EPS) are unwanted symptoms commonly originating from the use of certain medications. The symptoms can range from minimal discomfort to permanent involuntary muscular movements. The aims of the study were to examine the incidence of drug-induced extrapyramidal symptoms (di-EPS), associated risk factors, and clinical characteristics.

Methods: This is a retrospective, observational study of di-EPS conducted in outpatient clinics of Jordan using the longitudinal health database (Hakeem®) for data collection. Patients who received drugs with the risk of EPS during the period 2010-2020 were included and followed. Patients with any of the known underlying conditions that may cause EPS or were currently taking drugs that may mask the symptoms were excluded. Gender and age-matched control subjects were included in the study. The Statistical Package for Social Science (SPSS®) version 26 was used for data analysis.

Results: The final dataset included 34898 exposed patients and 69796 matched controls. The incidence of di-EPS ranged from 9.8% [Amitriptyline 25mg] to 28.9% (Imipramine 25mg). Baseline factors associated with a significantly higher risk of developing di-EPS were age {HR: 1.1 [95%CI: 0.8-1.2, p=0.003], smoking {HR: 1.7 (95%CI: 1.3-2.2), p=0.02}, tremor history {HR: 7.4 (95%CI: 5.9-8.3), p=.002} and history of taking antipsychotics {HR: 3.9, (95% CI: 2.5-4.6), p=0.001}. Patients taking paroxetine {HR: 8.6 [95%CI: 7.4-9.8], p=.0002},imipramine {HR: 8.3, [7.1-10.5], p=0.01}, or fluoxetine {HR: 8.2 (95%CI: 6.8-9.3), p=.006} had a significantly higher risk of developing di-EPS compared to patients taking citalopram. Myoclonus, blepharospasm, symptoms of the basal ganglia dysfunction, and organic writers' cramp were reported among participants.

Conclusion: Patients treated with paroxetine, imipramine, fluoxetine, or clomipramine had a higher risk of developing di-EPS than patients treated with citalopram. The difference in gender was not significantly related to di-EPS development. Whereas age, smoking, and history of taking antipsychotics were significantly associated with di-EPS development.

Key findings: • High incidence of drug-induced extrapyramidal symptoms (di-EPS) was reported• Age, smoking, tremor history, and history of taking antipsychotics were risk factors of drug-induced extrapyramidal symptoms.• Patients taking paroxetine, imipramine or fluoxetine had a significantly higher risk of developing di-EPS compared to patients taking citalopram.

Keywords: Antidepressant; Extrapyramidal symptom,Mental health; Jordan,Outpatient; Risk Factorsextrapyramidal symptom,Risk Factors.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Incidence of drug-induced extrapyramidal symptoms by treatment.
Fig. (2)
Fig. (2)
Number of di-EPS cases during the follow-up period.
Fig. (3)
Fig. (3)
Extrapyramidal Symptoms encountered in the exposed subjects.
See this image and copyright information in PMC

References

    1. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. Drug Saf. 2005;28(3):191–208. doi: 10.2165/00002018-200528030-00002. - DOI - PubMed
    1. Mathews M., Gratz S., Adetunji B., George V., Mathews M., Basil B. Antipsychotic-induced movement disorders: Evaluation and treatment. Psychiatry (Edgmont Pa.) 2005;2(3):36–41. - PMC - PubMed
    1. Muench J., Hamer A.M. Adverse effects of antipsychotic medications. Am. Fam. Physician. 2010;81(5):617–622. - PubMed
    1. Cha D.S., McIntyre R.S. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin. Pharmacother. 2012;13(11):1587–1598. doi: 10.1517/14656566.2012.656590. - DOI - PubMed
    1. Frances A., Weiden P. Promoting compliance with outpatient drug treatment. Hosp. Community Psychiatry. 1987;38(11):1158–1160. - PubMed

LinkOut - more resources